Sequence: YGRKKRRQRRR-GGG-KGLR-YFGAKRHRC-NH2
| Experiment Id | EXP001735 |
|---|---|
| Paper | Synthesis and antibacterial study of cell-penetrating peptide conjugated trifluoroacetyl and thioace |
| Peptide | Tat KP 15 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | Tested against bacteria across concentration ranges (e.g., 1000–1.9 µM for MIC assays; additional assays 0–50 µM for transcription inhibition). |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | Free peptide (no RNA payload; antibacterial study) |
| Formulation Components | Peptide alone in Mueller Hinton Broth (MHB) for MIC and biofilm assays; in vitro transcription assay with E. coli RNAP holoenzyme + plasmid DNA. |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Bacteria: Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa; yeast reporter strain TEL:URA3 for Sir2 inhibition screen. |
| Animal Model | |
| Administration Route | |
| Output Type | antibacterial activity + transcription inhibition (not RNA delivery) |
| Output Value | MICs reported vs S. aureus / E. coli / P. aeruginosa; Tat-conjugated peptides show higher potency than unconjugated analogs. |
| Output Units | |
| Output Notes | Tat-KP13 and Tat-KP24 fully inhibited in vitro transcription at ~10 µM in E. coli RNAP holoenzyme assay; biofilm inhibition/eradication and SEM/TEM membrane disruption also reported. |
| Toxicity Notes | Hemolysis <5% up to 1000 µM (mouse RBC). Tat conjugates cytotoxic to HeLa/BE(2)-C at ~17–32 µM IC50; unconjugated peptides less cytotoxic (~78–95 µM IC50). |
| Curation Notes |